Introduction {#H1-1-ZLD190019}
============

5α-reductase inhibitors (5-ARIs) are used to treat benign prostatic enlargement, a common condition causing urinary outflow obstruction.^[@zld190019r1]^ They also reduce prostate-specific antigen (PSA) by approximately 50%.^[@zld190019r2]^ Our group has recently published that among US military veterans, 5-ARIs are associated with delays in prostate cancer (PC) diagnoses, higher grade and stage at presentation, and worse PC-specific mortality (PCSM), presumably because of misinterpreted PSA values.^[@zld190019r3]^ We hypothesized that these results are generalizable to the broader US population.

Methods {#H1-2-ZLD190019}
=======

This cohort study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline. The study was considered exempt from review by the University of California, San Diego institutional review board because it used deidentified data. Data analysis was performed from February 1, 2019, through April 30, 2019.

We used the Surveillance, Epidemiology, and End Results Program--Medicare linked database and identified patients with stage I to IV PC and known PSA level at diagnosis between January 1, 2008, and December 31, 2013; no missing covariate information; and Medicare Part D coverage. Patients were required to have at least 1 year of prediagnosis Medicare enrollment for comorbidity assessment. All patients were followed up until death or December 31, 2015.

We extracted demographic and comorbidity variables, prescription drug information, and tumor-level variables. We defined 5-ARI use as any prescription of finasteride or dutasteride at least 6 months before a PC diagnosis. We doubled the PSA level for 5-ARI users per the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.^[@zld190019r4]^ We did not include in our models staging or treatment information as covariates because they are on the causal pathway between exposure and outcome.^[@zld190019r4]^

We tested for differences in covariates between exposure groups using χ^2^ and Wilcoxon rank sum tests. We used multivariable Fine-Gray competing risk regression models to obtain estimates of PCSM and noncancer mortality accounting for competing risk of death. We used multivariable Cox proportional hazards regression models to obtain hazard ratio (HR) estimates of all-cause mortality (ACM). Statistical tests were 2-sided, with *P* \< .05 considered statistically significant, and were conducted with SAS statistical software version 9.4 (SAS Institute Inc) and R statistical software version 3.5.1 (R Project for Statistical Computing).

Results {#H1-3-ZLD190019}
=======

The final cohort included 30 313 patients, with median (interquartile range) follow-up of 3.75 (2.33-5.25) years. A total of 2373 patients (7.83%) were prescribed 5-ARIs at least 6 months before PC diagnosis, with a median (interquartile range) treatment duration of 2.46 (1.45-3.74) years. The 4-year cumulative incidence of death from PC was 5.3% in 5-ARI users and 2.8% in nonusers.

Compared with participants who did not receive 5-ARI, those who did were more likely to present with disease that was high grade (Gleason score 8-10) (18% vs 29%, respectively; difference, 12%; 95% CI, 9%-13%; *P* \< .001), high risk (28% vs 38%; difference, 9%; 95% CI, 8%-11%; *P* \< .001), clinically node positive (2% vs 3%; difference, 1%; 95% CI, 0.6%-2%; *P* \< .001), and clinically metastatic (2% vs 3%; difference, 1%; 95% CI, 0.5%-2%; *P* \< .001). Furthermore, median (interquartile range) adjusted PSA level at diagnosis was significantly higher in 5-ARI users compared with nonusers (14.2 \[9.0-24.0\] ng/mL vs 6.6 \[4.8-10.2\] ng/mL; difference, 7.6 ng/mL; 95% CI, 7.0-8.2 ng/mL; *P* \< .001 \[to convert to micromoles per liter, multiply by 1.0\]) ([Table 1](#zld190019t1){ref-type="table"}).

###### Baseline Patient Characteristics at Prostate Cancer Diagnosis

  Characteristic                                                                                   No. (%)          *P* Value         
  ------------------------------------------------------------------------------------------------ ---------------- ----------------- --------
  Race                                                                                                                                
  Nonblack                                                                                         25 171 (90)      2208 (93)         \<.001
  Black                                                                                            2769 (10)        165 (7)           
  Age, median (IQR), y                                                                             72 (69-76)       74 (71-79)        \<.001
  Age, y                                                                                                                              
  66-70                                                                                            8215 (29)        416 (18)          \<.001
  71-74                                                                                            10 312 (37)      820 (35)          
  75-79                                                                                            5961 (21)        610 (26)          
  ≥80                                                                                              3452 (12)        527 (22)          
  Charlson Comorbidity Index score                                                                                                    
  0                                                                                                16 226 (58)      1243 (52)         \<.001
  ≥1                                                                                               11 714 (42)      1130 (48)         
  Census tract--level poverty rate                                                                                                    
  ≥20%                                                                                             5048 (18)        456 (19)          .17
  \<20%                                                                                            22 892 (82)      1917 (81)         
  Married                                                                                                                             
  No                                                                                               8616 (31)        797 (34)          .01
  Yes                                                                                              19 324 (69)      1576 (66)         
  α-Blocker[^a^](#zld190019t1n1){ref-type="table-fn"}                                                                                 
  No                                                                                               24 599 (88)      1032 (43)         \<.001
  Yes                                                                                              3341 (12)        1341 (57)         
  Statin[^a^](#zld190019t1n1){ref-type="table-fn"}                                                                                    
  No                                                                                               18 336 (66)      1011 (43)         \<.001
  Yes                                                                                              9604 (34)        1362 (57)         
  Nonaspirin NSAID^a^                                                                                                                 
  No                                                                                               23 252 (83)      1518 (64)         \<.001
  Yes                                                                                              4688 (17)        855 (36)          
  Year of diagnosis                                                                                                                   
  2008-2010                                                                                        14 942 (53)      900 (38)          \<.001
  2011-2013                                                                                        12 998 (47)      1473 (62)         
  PSA level at diagnosis, median (IQR), ng/mL                                                      6.6 (4.8-10.2)   7.1 (4.5-12.0)    \<.001
  Adjusted PSA level at diagnosis, median (IQR), ng/mL[^b^](#zld190019t1n2){ref-type="table-fn"}   6.6 (4.8-10.2)   14.2 (9.0-24.0)   \<.001
  Log PSA at diagnosis, mean (SD), log ng/mL                                                       1.99 (0.74)      2.01 (0.87)       .37
  Log adjusted PSA at diagnosis, mean (SD), log ng/mL                                              1.99 (0.74)      2.70 (0.87)       \<.001
  Gleason score                                                                                                                       
  NA                                                                                               1916 (7)         166 (7)           \<.001
  ≤7                                                                                               20 871 (75)      1525 (64)         
  ≥8                                                                                               5153 (18)        682 (29)          
  Risk group[^c^](#zld190019t1n3){ref-type="table-fn"}                                                                                
  Low                                                                                              7918 (28)        561 (24)          \<.001
  Intermediate                                                                                     12 095 (43)      917 (29)          
  High                                                                                             7927 (28)        895 (38)          
  Clinical T stage                                                                                                                    
  1-2                                                                                              25 925 (90)      2156 (91)         .63
  3-4                                                                                              2645 (10)        217 (9)           
  Clinical N stage                                                                                                                    
  0                                                                                                27 450 (98)      2303 (97)         \<.001
  1                                                                                                490 (2)          70 (3)            
  Clinical M stage                                                                                                                    
  0                                                                                                27 349 (98)      2296 (97)         \<.001
  1                                                                                                591 (2)          77 (3)            
  Hormone therapy                                                                                                                     
  No                                                                                               18 870 (67)      1388 (58)         \<.001
  Yes                                                                                              9070 (33)        985 (42)          
  Radiation therapy                                                                                                                   
  No                                                                                               11 504 (41)      991 (42)          .59
  Yes                                                                                              16 436 (59)      1382 (58)         
  Surgery                                                                                                                             
  No                                                                                               17 844 (64)      1521 (64)         .84
  Yes                                                                                              10 096 (36)      852 (36)          

Abbreviations: IQR, interquartile range; NA, not available; NSAID, nonsteroidal anti-inflammatory drug; PSA, prostate-specific antigen; 5-ARI, 5α-reductase inhibitor.

SI conversion factor: To convert PSA to μg/L, multiply by 1.0.

Medication use was defined as at least 1 prescription filled within the year before prostate cancer diagnosis.

To obtain adjusted PSA level, we multiplied the PSA for 5-ARI users by 2 to account for PSA suppression.

Low risk included patients with PSA level less than 10 ng/mL and Gleason group 6 and clinical T stage 1 or 2A; intermediate risk, PSA level greater than or equal to 10 ng/mL and PSA level less than or equal to 20 ng/mL or Gleason group of 7 or clinical T stage 2B or 2C; and high risk, PSA level greater than 20 ng/mL or Gleason group 8 or greater or clinical T stage greater than or equal to 3A.

Use of 5-ARIs was associated with an increased risk of PCSM (subdistribution HR, 1.38; 95% CI, 1.10-1.73; *P* = .005) and ACM (HR, 1.15; 95% CI, 1.01-1.30; *P* = .04). There were no differences in noncancer mortality (subdistribution HR, 1.06; 95% CI, 0.91-1.23; *P* = .47) ([Table 2](#zld190019t2){ref-type="table"}).

###### Prostate Cancer--Specific, Noncancer, and All-Cause Mortality

  Characteristic                                    Prostate Cancer--Specific Mortality   Noncancer Mortality   All-Cause Mortality                               
  ------------------------------------------------- ------------------------------------- --------------------- --------------------- -------- ------------------ --------
  5-ARI, yes vs no                                  1.38 (1.10-1.73)                      .005                  1.06 (0.91-1.23)      .47      1.15 (1.01-1.30)   .04
  α-Blocker, yes vs no                              1.13 (0.94-1.38)                      .17                   1.30 (1.16-1.45)      \<.001   1.24 (1.14-1.38)   \<.001
  Statin, yes vs no                                 1.07 (0.92-1.23)                      .39                   1.01 (0.92-1.11)      .82      1.03 (0.95-1.11)   .52
  Nonaspirin NSAID, yes vs no                       1.04 (0.87-1.25)                      .67                   1.03 (0.92-1.15)      .62      1.03 (0.94-1.14)   .53
  Charlson Comorbidity Index score, ≥1 vs 0         1.27 (1.11-1.46)                      \<.001                2.80 (2.56-3.06)      \<.001   2.23 (2.07-2.40)   \<.001
  Married, yes vs no                                0.72 (0.63-0.82)                      \<.001                0.63 (0.58-0.69)      \<.001   0.65 (0.61-0.70)   \<.001
  Age, y                                                                                                                                                          
  66-70                                             1 \[Reference\]                                             1 \[Reference\]                1 \[Reference\]    
  71-74                                             1.37 (1.09-1.71)                      .01                   1.31 (1.15-1.49)      \<.001   1.33 (1.18-1.48)   \<.001
  75-79                                             2.38 (1.91-2.97)                      \<.001                1.98 (1.73-2.26)      \<.001   2.08 (1.86-2.33)   \<.001
  ≥80                                               5.57 (4.51-6.89)                      \<.001                4.54 (3.99-5.15)      \<.001   4.80 (4.31-5.36)   \<.001
  Census tract--level poverty rate, ≥20% vs \<20%   1.43 (1.21-1.67)                      \<.001                1.50 (1.36-1.65)      \<.001   1.48 (1.36-1.61)   \<.001
  Year of diagnosis, 2011-2013 vs 2008-2010         0.97 (0.83-1.13)                      .67                   0.92 (0.83-1.03)      .14      0.94 (0.86-1.02)   .14
  Nonblack race vs black race                       0.77 (0.63-0.95)                      .02                   0.76 (0.67-0.85)      \<.001   0.76 (0.68-0.84)   \<.001

Abbreviations: HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drug; 5-ARI, 5α-reductase inhibitor.

Discussion {#H1-4-ZLD190019}
==========

This cohort study found that 5-ARI users presented with higher adjusted PSA levels and PC disease burden. They also had worse PCSM and ACM, but not worse noncancer mortality. These results are consistent with our recently published findings^[@zld190019r3]^ that observed that among US veterans, 5-ARI use was associated with worse PCSM (subdistribution HR, 1.39; 95% CI, 1.27-1.52; *P* \< .001) and ACM (HR, 1.10; 95% CI, 1.05-1.15; *P* \< .001). Like other studies,^[@zld190019r3],[@zld190019r4],[@zld190019r5],[@zld190019r6]^ we found that comorbidities, unmarried status, old age, low income, and black race were risk factors for PCSM, which adds validity to our findings. One study limitation included the possibility of misclassification bias, in which 5-ARIs were not used as prescribed.

Our results suggest a need for increased awareness of 5-ARI--induced PSA suppression, clearer guidelines for early PC detection, and systems-based mechanisms to help improve care for men using 5-ARIs.
